Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
暂无分享,去创建一个
Kevin J Anstrom | K. Anstrom | F. Martinez | G. Raghu | J. Lasky | T. King | Talmadge E King | Ganesh Raghu | Fernando J Martinez | Joseph A Lasky
[1] R. Barton. Inoperable brain metastases from non-small cell lung cancer: what part does whole brain radiotherapy play in standard treatment? , 2007, Thorax.
[2] A. Nicholson,et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.
[3] Johny Verschakelen,et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.
[4] J Rochon,et al. Application of GEE procedures for sample size calculations in repeated measures experiments. , 1997, Statistics in medicine.
[5] G. Raghu,et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. , 2008, American journal of respiratory and critical care medicine.
[6] David A. Lynch,et al. Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .
[7] Paul J. Friedman,et al. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.
[8] T. Beebe,et al. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. , 2008, Respiratory medicine.
[9] D. Lynch,et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.
[10] G. Hunninghake. Antioxidant therapy for idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.
[11] M. Raza. BUILD-1: A Randomized Placebo-Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis , 2009 .
[12] A. Wells,et al. Interstitial lung disease guideline , 2008, Thorax.
[13] A. Wells,et al. Acute Exacerbations of Idiopathic Pulmonary Fibrosis , 2013, Respiration.
[14] Geert Molenberghs,et al. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA , 2004, Clinical trials.
[15] G. Raghu,et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. , 2010, Respiratory medicine.
[16] J M Lachin,et al. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. , 1986, Biometrics.
[17] M. L. R. D. Christenson,et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management , 2012 .
[18] 马建新,et al. 用FEV6.0代替FVC诊断气道阻塞和肺功能受限[英]/Swanney MP…∥Am J Respir Crit Care Med. , 2002 .